BerGenBio ASA Statistics
Total Valuation
BerGenBio ASA has a market cap or net worth of NOK 426.05 million. The enterprise value is 225.93 million.
Market Cap | 426.05M |
Enterprise Value | 225.93M |
Important Dates
The next estimated earnings date is Wednesday, November 13, 2024.
Earnings Date | Nov 13, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
BerGenBio ASA has 39.09 million shares outstanding. The number of shares has increased by 1,817.19% in one year.
Shares Outstanding | 39.09M |
Shares Change (YoY) | +1,817.19% |
Shares Change (QoQ) | +33.41% |
Owned by Insiders (%) | 3.78% |
Owned by Institutions (%) | 6.25% |
Float | 24.70M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 605.66 |
PB Ratio | 2.43 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -1.45 |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.05
Current Ratio | 5.05 |
Quick Ratio | 4.93 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -85.55% and return on invested capital (ROIC) is -55.79%.
Return on Equity (ROE) | -85.55% |
Return on Assets (ROA) | -44.17% |
Return on Capital (ROIC) | -55.79% |
Revenue Per Employee | 34,733 |
Profits Per Employee | -10.36M |
Employee Count | 16 |
Asset Turnover | 0.00 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -3.37% in the last 52 weeks. The beta is 1.62, so BerGenBio ASA's price volatility has been higher than the market average.
Beta (5Y) | 1.62 |
52-Week Price Change | -3.37% |
50-Day Moving Average | 11.92 |
200-Day Moving Average | 24.15 |
Relative Strength Index (RSI) | 46.58 |
Average Volume (20 Days) | 254,814 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BerGenBio ASA had revenue of NOK 521,000 and -155.41 million in losses. Loss per share was -5.37.
Revenue | 521,000 |
Gross Profit | 521,000 |
Operating Income | -162.16M |
Pretax Income | -155.41M |
Net Income | -155.41M |
EBITDA | -161.94M |
EBIT | -162.16M |
Loss Per Share | -5.37 |
Balance Sheet
Cash & Cash Equivalents | 200.12M |
Total Debt | n/a |
Net Cash | 200.12M |
Net Cash Per Share | 5.12 |
Equity (Book Value) | 175.26M |
Book Value Per Share | 4.48 |
Working Capital | 175.04M |
Cash Flow
Operating Cash Flow | -175.69M |
Capital Expenditures | n/a |
Free Cash Flow | n/a |
FCF Per Share | n/a |
Margins
Gross Margin | 100.00% |
Operating Margin | -31,123.80% |
Pretax Margin | -29,828.21% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
BerGenBio ASA does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -1,817.19% |
Shareholder Yield | -1,817.19% |
Earnings Yield | -49.25% |
FCF Yield | n/a |
Stock Splits
The last stock split was on May 30, 2024. It was a reverse split with a ratio of 0.01.
Last Split Date | May 30, 2024 |
Split Type | Reverse |
Split Ratio | 0.01 |